0
Abstract: Poster Presentations |

EFFECT OF BUDESONIDE/FORMOTEROL PRESSURIZED METERED-DOSE INHALER BY AGE GROUP ON FORCED EXPIRATORY VOLUME IN 1 SECOND IN PATIENTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE FREE TO VIEW

Stephen I. Rennard, MD*; Donald P. Tashkin, MD; Jennifer McElhattan, MS; Ubaldo J. Martin, MD
Author and Funding Information

University of Nebraska Medical Center, Omaha, NE


Chest


Chest. 2009;136(4_MeetingAbstracts):95S. doi:10.1378/chest.136.4_MeetingAbstracts.95S
Text Size: A A A
Published online

Abstract

PURPOSE:  Disease progression and age-related loss of lung elastic recoil in chronic obstructive pulmonary disease (COPD) patients result in steadily increased airflow limitation. Age effects on response to budesonide/formoterol pressurized metered-dose inhaler (pMDI) were evaluated.

METHODS:  Two randomized, double-blind, multicenter studies (study I: 6-month; NCT00206154 [Tashkin et al. Drugs. 2008;68:1975]; study II: 12-month; NCT00206167 [Rennard et al. Drugs. 2009;69:549]) were conducted in moderate to very severe COPD patients ≥ 40 years. Changes from baseline (last predose FEV1 before randomized treatment) to treatment average in predose and 1-hour postdose FEV1 were assessed post hoc in 3 age groups: 40–64, 65–74, ≥ 75 years. Treatments included twice-daily budesonide/formoterol pMDI 320/9μg, budesonide/formoterol pMDI 160/9μg, budesonide pMDI 320μg + formoterol dry powder inhaler (DPI) 9μg (study I only), budesonide pMDI 320μg (study I only), formoterol DPI 9μg, placebo.

RESULTS:  Mean baseline predose FEV1 (L) decreased with age (1.06–1.14, 0.95–1.02, and 0.85–1.02 for patients 40–64 [study I, n = 907; study II, n = 1083], 65–74 [study I, n = 587; study II, n = 661], and ≥ 75 years [study I, n = 203; study II, n = 220], respectively). No consistent effect of age group on screening percentage predicted FEV1 (33.3%–35.4%, 32.1%–35.8%, 31.8%–36.4%, respectively) or percentage reversibility (14.9%–19.4%, 13.4%–19.8%, 13.1%–20.4%) was observed. Improvements in predose and postdose FEV1 for the indicated dose of budesonide/formoterol (320/9μg) were greater (predose: 12.1%–12.7%, 8.0%–9.8%, 5.8%–10.4%, respectively; postdose: 23.1%–27.0%, 20.6%–22.0%, 19.7%–21.6%) versus placebo (predose: 2.8%–4.5%, 0.0%–2.0%, −0.5%–1.7%; postdose: 5.1%–6.0%, 3.3% [both studies], 2.3%–6.2%). Percentage improvements generally were greater in 40–64 year olds; however, age-by-treatment interaction term on absolute mean changes was not significant.

CONCLUSION:  Predose and postdose FEV1 improved with the indicated budesonide/formoterol pMDI dose in all age groups.

CLINICAL IMPLICATIONS:  Older COPD patients (≥ 75 years) had lower baseline FEV1, similar screening percentage predicted FEV1, and lower percentage improvements in predose and postdose FEV1 with budesonide/formoterol pMDI versus younger patients. However, no effect of age group on absolute improvements was observed.

DISCLOSURE:  Stephen Rennard, Grant monies (from industry related sources) AstraZeneca, Biomark, Centocor, Novartis; Consultant fee, speaker bureau, advisory committee, etc. Almirall, Aradigm, AstraZeneca, Boehringer Ingelheim, Defined Health, Dey, Eaton Associates, GlaxoSmithKline, Medacorp, Mpex, Novartis, Nycomed, Otsuka, Pfizer, Pulmatrix, Theravance, United Biosource, Uptake Medical, Vantage Point; Other Speaker for AstraZeneca, Novartis, Netrowk for Continuing Education, Pfizer, SOMA; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543